|
miR-126 Inhibitor miRisten Clinical Trials
1 actively recruiting trial across 1 location
Also known as: CpG-linked Anti-Mir-126 Oligonucleotide, miRisten; Oligodeoxynucleotide Anti-miR-126 Inhibitor miRisten; MicroRNA-126 Inhibitor miRisten; CpG(D19)-Anti-miR-126; ODN-based CpG-Anti-miRNA-126;
Duarte, California1 trial
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.